Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 12 September 2017

Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Targovax ASA    

Published: 15:48 CEST 12-09-2017 /GlobeNewswire /Source: Targovax ASA / : TRVX /ISIN: NO0010689326

Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start of patient recruitment in phase I/II study to investigate the safety, biologic and anti-tumor activity of  trial of ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies.

 

The sponsor of the study is Ludwig Institute for Cancer Research.

 

For further information regarding the trial, please visit ClinicalTrials.Gov.

 

 

 

For further information, please contact:

Renate Birkeli, Investor Relations

Phone: +47 922 61 624

Email: renate.birkeli@targovax.com  

 

Media and IR enquires:

Jan Petter Stiff - Crux Advisers (Norway)

Phone: +47 995 13 891

Email: stiff@crux.no   

 

Julia Phillips/Simon Conway - FTI Consulting (International)

Phone: +44 20 3727 1000

Email: Targovax@fticonsulting.com 

 

 

 

About Targovax

 

Arming the patient's immune system to fight cancer

 

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

 

The Company's development pipeline is based on two novel proprietary platforms:

 

The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS exclusively uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I studies it has demonstrated immune activation at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.

 

The second, TG, is a target specific, neo-antigen therapeutic cancer vaccine platform that solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform's therapeutic potential stems from its ability to enable a patient's immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.

 

Targovax's development pipeline has three novel therapeutic candidates in clinical development covering six indications.

 

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.

 

In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares moved to Oslo Børs, the main Oslo Stock Exchange.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.




This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Targovax ASA, Lilleakerveien 2c, Oslo 0283, Norway
If you would like to unsubscribe and stop receiving these e-mails click here.